Last reviewed · How we verify
NCT05207475
Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA)
NA trial testing Remote ischemic conditioning in Cerebral Amyloid Angiopathy in 30 participants. Status unknown.
20 January 2022
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 January 2022 |
| Primary completion | 20 January 2022 |
| Estimated completion | 20 January 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Remote ischemic conditioning
Conditions studied
- Cerebral Amyloid Angiopathy — all drugs for Cerebral Amyloid Angiopathy →
Sponsor
Capital Medical University
Who can join
Adults 55 to 85, any sex, with Cerebral Amyloid Angiopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebral amyloid angiopathy (CAA) is a common form of cerebral small vessel disease, characterized by symptomatic intracerebral hemorrhage and cognitive impairment. However, no effective prevention and treatment strategies have been established. This study aims to evaluate the safety and efficacy of remote ischemic conditioning on patients with CAA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05207475
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remote ischemic conditioning
Trials testing the same drug.
- NCT03484936 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage · NA · not yet recruiting
- NCT07412249 — Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis · NA · recruiting
- NCT03669653 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke · NA · not yet recruiting
- NCT06702644 — Safety and Efficacy of Remote Ischemic Conditioning in Patients with Chronic Internal Carotid Artery Occlusion Receiving · NA · not yet recruiting
- NCT06171334 — Remote Ischemic Conditioning in PPMS · NA · not yet recruiting
Other recruiting trials for Cerebral Amyloid Angiopathy
Currently open trials in the same condition.
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06393712 — A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · Phase 2 · recruiting
- NCT05734378 — Prognosis of Cerebral Small Vessel Disease · recruiting
- NCT04204642 — SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) · recruiting
- NCT06128824 — High Frequency Imaging in Cerebral Amyloid Angiopathy · active not recruiting
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05207475 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 26 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207475.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing